NAV

Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone

Identification

Generic Name
Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
DrugBank Accession Number
DB02872
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 686.434
Monoisotopic: 684.09468089
Chemical Formula
C31H34Br2N4O4
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UE3 ubiquitin-protein ligase Mdm2Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Piperazine carboxamides / Anisoles / Methoxybenzenes / Phenoxy compounds / Alkyl aryl ethers / Bromobenzenes / N-alkylpiperazines / Aryl bromides / Imidazolines / Ureas
show 11 more
Substituents
1,2-aminoalcohol / 1,4-diazinane / 2-imidazoline / Alcohol / Alkanolamine / Alkyl aryl ether / Amidine / Amine / Anisole / Aromatic heteromonocyclic compound
show 33 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
PVRYEWOXWGDQHA-URLMMPGGSA-N
InChI
InChI=1S/C31H34Br2N4O4/c1-3-41-27-20-25(40-2)12-13-26(27)30-34-28(21-4-8-23(32)9-5-21)29(22-6-10-24(33)11-7-22)37(30)31(39)36-16-14-35(15-17-36)18-19-38/h4-13,20,28-29,38H,3,14-19H2,1-2H3/t28-,29+/m0/s1
IUPAC Name
2-{4-[(4S,5R)-4,5-bis(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl]piperazin-1-yl}ethan-1-ol
SMILES
[H][C@]1(N=C(N(C(=O)N2CCN(CCO)CC2)[C@]1([H])C1=CC=C(Br)C=C1)C1=C(OCC)C=C(OC)C=C1)C1=CC=C(Br)C=C1

References

General References
Not Available
PubChem Compound
5288631
PubChem Substance
46507913
ChemSpider
4450754
BindingDB
50392531
ChEMBL
CHEMBL407632
ZINC
ZINC000028467964
PDBe Ligand
IMZ
PDB Entries
1rv1

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00547 mg/mLALOGPS
logP5.06ALOGPS
logP5.52Chemaxon
logS-5.1ALOGPS
pKa (Strongest Acidic)15.59Chemaxon
pKa (Strongest Basic)6.77Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area77.84 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity166.88 m3·mol-1Chemaxon
Polarizability65.61 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9915
Blood Brain Barrier+0.5935
Caco-2 permeable-0.5361
P-glycoprotein substrateSubstrate0.8255
P-glycoprotein inhibitor INon-inhibitor0.5093
P-glycoprotein inhibitor IIInhibitor0.6315
Renal organic cation transporterInhibitor0.5308
CYP450 2C9 substrateNon-substrate0.7307
CYP450 2D6 substrateNon-substrate0.8218
CYP450 3A4 substrateSubstrate0.5999
CYP450 1A2 substrateNon-inhibitor0.7705
CYP450 2C9 inhibitorNon-inhibitor0.659
CYP450 2D6 inhibitorNon-inhibitor0.8227
CYP450 2C19 inhibitorNon-inhibitor0.7251
CYP450 3A4 inhibitorNon-inhibitor0.7628
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5508
Ames testNon AMES toxic0.6789
CarcinogenicityNon-carcinogens0.7377
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6041 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6617
hERG inhibition (predictor II)Inhibitor0.662
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0000009000-fca9813089f52613bbde
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0000009000-6683c2e964959134ab44
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0000009000-840d6bfb771ba2520fa6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00c9-2000009000-4eb4d6507be794f21bd6
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0470-2902057000-c3fc06f531e7af2ab781
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9100047000-0edf9226784785a51ab7
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-234.60994
predicted
DeepCCS 1.0 (2019)
[M+H]+236.82684
predicted
DeepCCS 1.0 (2019)
[M+Na]+242.60875
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. E3 ubiquitin-protein ligase Mdm2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by bindi...
Gene Name
MDM2
Uniprot ID
Q00987
Uniprot Name
E3 ubiquitin-protein ligase Mdm2
Molecular Weight
55232.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52